Statistical Basis for Hemochromatosis Screening
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · May 25, 2000
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Once considered to be a rare disorder, hemochromatosis is now recognized to be one of the most common autosomal recessive disorders in white populations. Substantial morbidity and mortality may result from untreated hemochromatosis; thus, early detection and treatment are essential. The Centers for Disease Control and Prevention and the College of American Pathologists now recommend regular screening for hereditary hemochromatosis. Transferrin saturation is regarded as the best single screening test for the detection of individuals at risk for the disorder.
DESIGN NARRATIVE:
...
Gender
ALL
Eligibility criteria
- • No eligibility criteria
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Christine Mc Laren
Moorhead State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials